[{"orgOrder":0,"company":"Alphamab Oncology","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"KN026","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alphamab Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Alphamab Oncology \/ Alphamab Oncology","highestDevelopmentStatusID":"7","companyTruncated":"Alphamab Oncology \/ Alphamab Oncology"},{"orgOrder":0,"company":"Alphamab Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"KN046","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Alphamab Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Alphamab Oncology \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Alphamab Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Alphamab Oncology","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"Docetaxel","moa":"HER2 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Alphamab Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Alphamab Oncology \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Alphamab Oncology \/ Sanofi"},{"orgOrder":0,"company":"Alphamab Oncology","sponsor":"Institut Pasteur Shanghai","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2020","type":"Partnership","leadProduct":"COVID-19 neutralizing antibody","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Alphamab Oncology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Alphamab Oncology \/ Institut Pasteur Shanghai","highestDevelopmentStatusID":"1","companyTruncated":"Alphamab Oncology \/ Institut Pasteur Shanghai"},{"orgOrder":0,"company":"Alphamab Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"KN046","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"Alphamab Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Alphamab Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Alphamab Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Alphamab Oncology","sponsor":"Jiangsu Alphamab Biopharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"KN046","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"Alphamab Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Alphamab Oncology \/ Jiangsu Alphamab Biopharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Alphamab Oncology \/ Jiangsu Alphamab Biopharmaceuticals"},{"orgOrder":0,"company":"Alphamab Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"KN046","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alphamab Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alphamab Oncology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Alphamab Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Alphamab Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"KN046","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Alphamab Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alphamab Oncology \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Alphamab Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Alphamab Oncology","sponsor":"TRACON Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Envafolimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"Alphamab Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alphamab Oncology \/ Alphamab Oncology","highestDevelopmentStatusID":"8","companyTruncated":"Alphamab Oncology \/ Alphamab Oncology"},{"orgOrder":0,"company":"Alphamab Oncology","sponsor":"TRACON Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Envafolimab","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Alphamab Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Alphamab Oncology \/ Alphamab Oncology","highestDevelopmentStatusID":"8","companyTruncated":"Alphamab Oncology \/ Alphamab Oncology"},{"orgOrder":0,"company":"Jiangsu Alphamab","sponsor":"Glenmark Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Envafolimab","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Jiangsu Alphamab","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jiangsu Alphamab \/ Glenmark Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Jiangsu Alphamab \/ Glenmark Pharmaceuticals"},{"orgOrder":0,"company":"Alphamab Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"JSKN003","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alphamab Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alphamab Oncology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Alphamab Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Alphamab Oncology","sponsor":"Arrivent","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"Antibody-drug Conjugate","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Alphamab Oncology","amount2":0.62,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.62,"dosageForm":"","sponsorNew":"Alphamab Oncology \/ ArriVent","highestDevelopmentStatusID":"2","companyTruncated":"Alphamab Oncology \/ ArriVent"}]

Find Clinical Drug Pipeline Developments & Deals by Alphamab Oncology

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : Through the collaboration, both companies will leverage Alphamab’s proprietary linker-payload platform and glycan-conjugation technology to identify novel ADCs for oncology indications.

                          Brand Name : Undiclosed

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          June 05, 2024

                          Lead Product(s) : Antibody-drug Conjugate

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery

                          Sponsor : Arrivent

                          Deal Size : $615.5 million

                          Deal Type : Collaboration

                          blank

                          02

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : JSKN003 is an anti-HER2 bispecific antibody-drug conjugate, which is currently being evaluated for the treatment of HER2-expressing advanced solid tumors.

                          Brand Name : JSKN003

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          May 06, 2024

                          Lead Product(s) : JSKN003

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : Glenmark is responsible for developing, registering, and commercializing KN035 (envafolimab) outside of China for MSI-H or dMMR advanced solid tumors in previously treated adults.

                          Brand Name : KN035

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          January 25, 2024

                          Lead Product(s) : Envafolimab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Glenmark Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          04

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : KN035 (envafolimab) is a single-domain antibody against PD-L1 invented by Alphamab Oncology and licensed by TRACON, is the first approved subcutaneously injected PD-(L)1 inhibitor, which is investigated for MSI-H/dMMR advanced solid tumors.

                          Brand Name : KN035

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          June 20, 2023

                          Lead Product(s) : Envafolimab,Ipilimumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Recipient : TRACON Pharmaceuticals

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : Result demonstrated highly tolerable safety profile and significantly higher objective response rate observed in lower weight patients in ENVASARC, to increase dose of envafolimab to 600 mg every three weeks, which is double the original envafolimab dose...

                          Brand Name : KN035

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          April 19, 2022

                          Lead Product(s) : Envafolimab,Ipilimumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Recipient : TRACON Pharmaceuticals

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          06

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : KN046-204 is a phase II clinical study in China to evaluate the efficacy and safety of KN046 monotherapy or plus chemotherapy for unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma.

                          Brand Name : KN046

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          June 07, 2021

                          Lead Product(s) : KN046

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : KN046-203 is a phase Ib/II, open label, multi-center clinical study, evaluating the efficacy, safety, and tolerability of KN046 in combination with nab-paclitaxel in patients with TNBC.

                          Brand Name : KN046

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          April 13, 2021

                          Lead Product(s) : KN046,Paclitaxel

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          08

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : KN046 is a bispecific antibody targeting PD-L1 and CTLA-4 immune checkpoints. Alphamab will conduct a open label, multi-center phase II pivotal clinical study in the U.S to evaluate the efficacy, safety and tolerability of KN046 for the treatment of thy...

                          Brand Name : KN046

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          March 09, 2021

                          Lead Product(s) : KN046

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Jiangsu Alphamab Biopharmaceuticals

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          09

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : The recombinant humanized PD-L1/ CTLA-4 bispecific antibody KN046 was granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for the treatment of thymic epithelial tumors.

                          Brand Name : KN046

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          September 03, 2020

                          Lead Product(s) : KN046

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          10

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : According to the agreement, Alphamab Oncology and Institut Pasteur Shanghai will form a joint project team. Alphamab Oncology is responsible for providing its proprietary Mixed Antibodies Platform, constructing humanized antibodies and recombinant engine...

                          Brand Name : Undisclosed

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          June 10, 2020

                          Lead Product(s) : COVID-19 neutralizing antibody

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Undisclosed

                          Sponsor : Institut Pasteur Shanghai

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank